JP2010520881A - 黒色腫の処置 - Google Patents

黒色腫の処置 Download PDF

Info

Publication number
JP2010520881A
JP2010520881A JP2009552899A JP2009552899A JP2010520881A JP 2010520881 A JP2010520881 A JP 2010520881A JP 2009552899 A JP2009552899 A JP 2009552899A JP 2009552899 A JP2009552899 A JP 2009552899A JP 2010520881 A JP2010520881 A JP 2010520881A
Authority
JP
Japan
Prior art keywords
melanoma
compound
reaction
group
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009552899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520881A5 (enExample
Inventor
カーラ・シー・ヘイズ
ポール・ホーレンバッハ
ダニエル・メネゼス
ナンシー・プライアー
キャサリン・レンダール
マリオン・ウィースマン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39500684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010520881(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010520881A publication Critical patent/JP2010520881A/ja
Publication of JP2010520881A5 publication Critical patent/JP2010520881A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009552899A 2007-03-09 2008-03-07 黒色腫の処置 Pending JP2010520881A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89404607P 2007-03-09 2007-03-09
US91140607P 2007-04-12 2007-04-12
PCT/US2008/056122 WO2008112509A1 (en) 2007-03-09 2008-03-07 Treatment of melanoma

Publications (2)

Publication Number Publication Date
JP2010520881A true JP2010520881A (ja) 2010-06-17
JP2010520881A5 JP2010520881A5 (enExample) 2011-04-21

Family

ID=39500684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552899A Pending JP2010520881A (ja) 2007-03-09 2008-03-07 黒色腫の処置

Country Status (11)

Country Link
US (1) US20100086518A1 (enExample)
JP (1) JP2010520881A (enExample)
KR (1) KR20090119768A (enExample)
AU (1) AU2008226582B2 (enExample)
BR (1) BRPI0808714A2 (enExample)
CA (1) CA2679268A1 (enExample)
CL (1) CL2008000681A1 (enExample)
MX (1) MX2009009574A (enExample)
RU (1) RU2009136669A (enExample)
TW (1) TW200843766A (enExample)
WO (1) WO2008112509A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527322A (ja) * 2008-07-08 2011-10-27 サノフイ−アベンテイス Ｆｇｆ−ｒ４受容体特異的拮抗薬

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
TR201810944T4 (tr) 2013-10-25 2018-08-27 Novartis Ag Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
WO2016053249A1 (en) 2014-09-29 2016-04-07 Hewlett-Packard Development Company, L.P. Hinge assembly with compressible sleeve
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3103450A1 (en) 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN108610293B (zh) * 2018-06-15 2020-08-04 南京工业大学 一种采用微通道反应装置制备多韦替尼中间体的方法
WO2024097855A2 (en) * 2022-11-03 2024-05-10 University Of Florida Research Foundation, Incorporated Identification of small molecules that recruit and activate rnase l

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511616A (ja) * 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
JP2006513223A (ja) * 2002-12-24 2006-04-20 ニューヨーク・ユニバーシティ ｐ−アミノ安息香酸（ＰＡＢＡ）によるメラニン形成及びメラノーマ転移の阻害

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762475A1 (en) * 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
EP2368566A1 (en) * 2006-07-13 2011-09-28 ZymoGenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
EP2049904A1 (en) * 2006-07-28 2009-04-22 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511616A (ja) * 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
JP2006513223A (ja) * 2002-12-24 2006-04-20 ニューヨーク・ユニバーシティ ｐ−アミノ安息香酸（ＰＡＢＡ）によるメラニン形成及びメラノーマ転移の阻害

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013003642; ＬＥＧＨＡ，Ｓ．Ｓ．　ｅｔ　ａｌ: 'Ｔｒｅａｔｍｅｎｔ　ｏｆ　ｍｅｔａｓｔａｔｉｃ　ｍｅｌａｎｏｍａ　ｗｉｔｈ　ｃｏｍｂｉｎｅｄ　ｃｈｅｍｏｔｈｅｒａｐｙ　ｃｏｎｔａｉｎｉｎｇ　ｃｉｓｐｌａｔｉｎ，　ｖｉｎｂｌａｓｔｉｎｅ　ａｎｄ　ｄａ' Ａｎｎ　Ｏｎｃｏｌ Ｖｏｌ．７，　Ｎｏ．８, 1996, ｐ．８２７-３５ *
JPN6013003643; ＨＯＤＩ，Ｆ．Ｓ．　ｅｔ　ａｌ: 'Ｐｈａｓｅ　ＩＩ　ｓｔｕｄｙ　ｏｆ　ｐａｃｌｉｔａｘｅｌ　ａｎｄ　ｃａｒｂｏｐｌａｔｉｎ　ｆｏｒ　ｍａｌｉｇｎａｎｔ　ｍｅｌａｎｏｍａ' Ａｍ　Ｊ　Ｃｌｉｎ　Ｏｎｃｏｌ Ｖｏｌ．２５，　Ｎｏ．３, 2002, ｐ．２８３-６ *
JPN6013003644; ＲＡＯ，Ｒ．Ｄ．　ｅｔ　ａｌ: 'Ｃｏｍｂｉｎａｔｉｏｎ　ｏｆ　ｐａｃｌｉｔａｘｅｌ　ａｎｄ　ｃａｒｂｏｐｌａｔｉｎ　ａｓ　ｓｅｃｏｎｄ-ｌｉｎｅ　ｔｈｅｒａｐｙ　ｆｏｒ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｍｅｔａｓｔａｔｉｃ　ｍｅｌａｎｏ' Ｃａｎｃｅｒ Ｖｏｌ．１０６，　Ｎｏ．２, 2006, ｐ．３７５-８２ *
JPN6013003645; ＸＩＮ，Ｘ．　ｅｔ　ａｌ: 'ＣＨＩＲ-２５８　ｅｆｆｉｃａｃｙ　ｉｎ　ａ　ｎｅｗｌｙ　ｄｅｖｅｌｏｐｅｄ　ｐｒｅｃｌｉｎｉｃａｌ　ｂｏｎｅ　ｍａｒｒｏｗ　ｍｏｄｅｌ　ｏｆ　ｔ（４；１４）　ｍｕｌｔｉｐｌｅ　ｍｙｅｌｏｍａ' Ｂｌｏｏｄ Ｖｏｌ．１０６，　Ｎｏ．１１, 2005, ｐ．９６３Ａ *
JPN6013003646; ＣＨＡＮＤＬＥＲ，Ｌ．Ａ．　ｅｔ　ａｌ: 'Ｐｒｅｖａｌｅｎｔ　ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｆｉｂｒｏｂｌａｓｔ　ｇｒｏｗｔｈ　ｆａｃｔｏｒ　（ＦＧＦ）　ｒｅｃｅｐｔｏｒｓ　ａｎｄ　ＦＧＦ２　ｉｎ　ｈｕｍａｎ　ｔｕｍｏｒ　ｃｅｌｌ　ｌｉｎｅｓ' Ｉｎｔ　Ｊ　Ｃａｎｃｅｒ Ｖｏｌ．８１，　Ｎｏ．３, 1999, ｐ．４５１-８ *
JPN6013003647; 福島雅典監修，　メルクマニュアル第１８版日本語版，　日経ＢＰ社，　２００６，　ｐ．１０７９-８１ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527322A (ja) * 2008-07-08 2011-10-27 サノフイ−アベンテイス Ｆｇｆ−ｒ４受容体特異的拮抗薬

Also Published As

Publication number Publication date
US20100086518A1 (en) 2010-04-08
CL2008000681A1 (es) 2008-10-24
KR20090119768A (ko) 2009-11-19
RU2009136669A (ru) 2011-04-20
BRPI0808714A2 (pt) 2014-08-12
WO2008112509A1 (en) 2008-09-18
AU2008226582B2 (en) 2011-07-21
MX2009009574A (es) 2009-09-16
TW200843766A (en) 2008-11-16
CA2679268A1 (en) 2008-09-18
AU2008226582A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
AU2008226582B2 (en) Treatment of melanoma
KR101167573B1 (ko) 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
AU2011237642B2 (en) Antimetastatic compounds
US20100173873A1 (en) Treatment of metastasized tumors
AU2006247803B2 (en) Methods for treating drug resistant cancer
CN101641097A (zh) 黑素瘤的治疗
CN116685324A (zh) 用于预防或治疗与ron突变相关的胰腺癌的药物组合物及其使用方法
HK1155664B (en) Treatment of metastasized tumors
CN101146538A (zh) 转移瘤的治疗
HK1117047A (en) Treatment of metastasized tumors
HK1110477B (en) Methods for treating drug resistant cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702